

Neung Hwa Park

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5099995/publications.pdf>

Version: 2024-02-01

39
papers

1,030
citations

516710

16
h-index

434195

31
g-index

44
all docs

44
docs citations

44
times ranked

1999
citing authors

#	ARTICLE	IF	CITATIONS
1	A Multi-Center, Double-Blind Randomized Controlled Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802 (Tenofovir Disoproxil Orotate) and Viread (Tenofovir Disoproxil) Tj ETQq1 1 0.7843 145rgBT /Overlock 10		
2	Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: A propensity score-matched analysis. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 254-264.	8.9	18
3	Comparable Incidence of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1739-1750.	2.3	15
4	Welfare Genome Project: A Participatory Korean Personal Genome Project With Free Health Check-Up and Genetic Report Followed by Counseling. <i>Frontiers in Genetics</i> , 2021, 12, 633731.	2.3	6
5	Clinical usefulness of noninvasive fibrosis indices for predicting hepatocellular carcinoma in treatment-naïve patients with chronic hepatitis B following entecavir therapy. <i>Hepatology Research</i> , 2021, 51, 923-932.	3.4	1
6	Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance. <i>EBioMedicine</i> , 2020, 58, 102926.	6.1	10
7	Real-World Efficacy and Safety of Lenvatinib in Korean Patients with Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Analysis. <i>Liver Cancer</i> , 2020, 9, 613-624.	7.7	45
8	Korean Genome Project: 1094 Korean personal genomes with clinical information. <i>Science Advances</i> , 2020, 6, eaaz7835.	10.3	75
9	Low-level viremia and cirrhotic complications in patients with chronic hepatitis B according to adherence to entecavir. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 364-375.	8.9	26
10	Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1850-1859.e4.	4.4	45
11	Tonicity-responsive enhancer-binding protein promotes hepatocellular carcinogenesis, recurrence and metastasis. <i>Gut</i> , 2019, 68, 347-358.	12.1	39
12	Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study. <i>Journal of Hepatology</i> , 2018, 68, 1018-1024.	3.7	109
13	Chronic Hepatitis B Infection Is Significantly Associated with Chronic Kidney Disease: a Population-based, Matched Case-control Study. <i>Journal of Korean Medical Science</i> , 2018, 33, e264.	2.5	13
14	The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B. <i>Liver International</i> , 2018, 38, 2269-2276.	3.9	18
15	Mortality, liver transplantation and hepatic complications in patients with treatment-naïve chronic hepatitis B treated with entecavir vs tenofovir. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1565-1575.	2.0	58
16	Medication Nonadherence Increases Hepatocellular Carcinoma, Cirrhotic Complications, and Mortality in Chronic Hepatitis B Patients Treated With Entecavir. <i>American Journal of Gastroenterology</i> , 2018, 113, 998-1008.	0.4	44
17	Clinical Course of Partial Virologic Response with Prolonged Tenofovir Therapy in Nucl(t)ides-Naïve Patients with Chronic Hepatitis B. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2908-2914.	2.3	7
18	Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 230-238.	8.9	13

#	ARTICLE	IF	CITATIONS
19	Comparison of tenofovir plus lamivudine versus tenofovir monotherapy in patients with lamivudine-resistant chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 152-159.	8.9	0
20	Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth. <i>Journal of Immunology</i> , 2016, 196, 2410-2423.	0.8	86
21	DRG2 Regulates G2/M Progression via the Cyclin B1-Cdk1 Complex. <i>Molecules and Cells</i> , 2016, 39, 699-704.	2.6	52
22	Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1514-1521.	2.8	11
23	Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. <i>Clinical Therapeutics</i> , 2015, 37, 1433-1442.	2.5	7
24	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 526-532.	3.7	46
25	Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1228-1234.	2.1	9
26	Mutational analysis of FEN1 Gene in hepatocellular carcinomas. <i>Apmis</i> , 2014, 122, 663-665.	2.0	4
27	Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B. <i>Hepatology</i> , 2014, 59, 1912-1920.	7.3	29
28	Reply. <i>Hepatology</i> , 2014, 60, 2132-2134.	7.3	0
29	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (80% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. <i>Hepatology International</i> , 2013, 7, 1000-1009.	4.2	2
30	Clinical course of patients with insufficient viral suppression during entecavir therapy in genotype C chronic hepatitis B. <i>Digestive and Liver Disease</i> , 2013, 45, 600-605.	0.9	15
31	Topical application of capsaicin reduces visceral adipose fat by affecting adipokine levels in high-fat diet-induced obese mice. <i>Obesity</i> , 2013, 21, 115-122.	3.0	79
32	Performance Evaluation of 3 Kinds of HBsAg Qualitative Assays and 2 Kinds of Quantitative Assays. <i>Laboratory Medicine Online</i> , 2013, 3, 160.	0.2	0
33	HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance. <i>Antiviral Therapy</i> , 2011, 17, 387-394.	1.0	10
34	The Level of HBV DNA at Month 12 Is an Important Predictor of Virological Breakthrough During Adefovir Monotherapy in Chronic Hepatitis B Patients with Lamivudine Resistance. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1215-1221.	2.3	6
35	Impacts of Vaccination on Hepatitis B Viral Infections in Korea over a 25-Year Period. <i>Intervirology</i> , 2010, 53, 20-28.	2.8	80
36	Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States Tong MJ, Hsien C, Hsu L, Sun HE, Blatt LM. <i>The Korean Journal of Hepatology</i> , 2009, 15, 106.	1.5	1

#	ARTICLE	IF	CITATIONS
37	Clinical usefulness of sequential hepatitis B virus DNA measurement (the roadmap concept) during adefovir treatment in lamivudine-resistant patients. <i>Antiviral Therapy</i> , 2009, 14, 181-186.	1.0	11
38	Mitotic checkpoint gene MAD1 in hepatocellular carcinoma is associated with tumor recurrence after surgical resection. <i>Journal of Surgical Oncology</i> , 2008, 97, 567-571.	1.7	11
39	Molecular Pathogenesis of Hepatitis-B-virus-associated Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2007, 1, 101-117.	2.9	16